European Archives - Page 917 of 981 - European Medical Journal

EMJ

New Blood Tests May Quickly Diagnose IBS

DIAGNOSIS of irritable bowel syndrome (IBS), the most common gastroenterological condition in the USA, can now be achieved with just two blood tests…

ENDEAVOR: A phase 3 study of carfilzomib in relapsed myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain…

Results of the phase 4 EXELS study of high-risk patients with essential thrombocythemia

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust…

Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…

EMJ

Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

EMJ

Phase 2 MMY2002 trial of daratumumab in myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca…

EMJ

Results of the phase 3 ELOQUENT-2 trial

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…

EMJ

Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…

EMJ

Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…

EMJ

DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse

Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…